Skip to main content
An official website of the United States government
Email

Cancer Immunoprevention Network (CIP-Net)

An image of T cells interacting with dendritic cells.

A dendritic cell (blue) showing T cells (red) what antigens to look for. This helps T cells find cancer cells and infected cells.

Credit: National Institute of Allergy and Infectious Diseases

An emerging scientific opportunity is the development of approaches that leverage the immune system to prevent cancers. Further, an NCI Board of Scientifc Advisors (BSA) Ad Hoc Working Group encouraged fostering “novel and innovative research designs….to expedite progress in precision prevention.”

The Cancer Immunoprevention Network (CIP-Net), supported by DCB and the NCI Division of Cancer Prevention, is advancing a deeper understanding of basic mechanisms of immunoprevention, promoting the discovery of novel immunoprevention strategies, and fostering a community of cancer immunoprevention researchers.

Additional details about the network can be found on NCI Division of Cancer Prevention webpages about CIP-Net. 
 

CIP-Net News

New UG3/UH3 grants for CIP-Net were awarded in Summer 2024.

Drs. Madhav Dhodapkar, Richard Flavell, and Noah Palm with the Emory University CIP-Net Project are investigating and targeting microbial triggers of monoclonal gammopathy of undetermined significance (a precursor state to multiple myeloma) for immunoprevention.

The Icahn School of Medicine at Mount Sinai CIP-Net Project, led by Drs. Nina Bhardwaj, Aimee Lucas, and Robert Samstein, is examining immune determinants modulating cancer development in Lynch syndrome (an inherited disorder that increases the risk for cancer) to inform the design of cancer prevention/interception strategies.

Dr. Shadmehr Demehri with the Massachusetts General Hospital CIP-Net Project is studying mechanisms that regulate immunosurveillance in BRCA mutant breast glands and developing strategies for breast cancer immunoprevention. 

The University of Missouri-Columbia CIP-Net Project, led by Drs. Haval Shirwan and Esma Yolcu, is developing and testing a new immune activating agent for cancer prevention in preclinical models. 

DCB Contact for CIP-Net

For additional information about CIP-Net, please contact Dr. Lillian Kuo.

Funded Projects

Institution Principal Investigator(s) Center Title
Emory University Madhav V. Dhodapkar, Richard A. Flavell, Noah. W. Palm Targeting microbial triggers of gammopathy for immunoprevention
Icahn School of Medicine at Mount Sinai Nina Bhardwaj, Aimee L. Lucas, Robert M. Samstein Immune determinants modulating cancer development in Lynch Syndrome
Massachusetts General Hospital Shadmehr Demehri Immunosurveillance of breast glands with oncogenic germline mutations
University of Missouri-Columbia Haval Shirwan, Esma S. Yolcu Developing a novel agonist of CD137 for cancer immunoprevention

 

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Cancer Immunoprevention Network (CIP-Net) was originally published by the National Cancer Institute.”

Email